Nature Communications (Jul 2022)
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
- Ian D. Ferguson,
- Bonell Patiño-Escobar,
- Sami T. Tuomivaara,
- Yu-Hsiu T. Lin,
- Matthew A. Nix,
- Kevin K. Leung,
- Corynn Kasap,
- Emilio Ramos,
- Wilson Nieves Vasquez,
- Alexis Talbot,
- Martina Hale,
- Akul Naik,
- Audrey Kishishita,
- Priya Choudhry,
- Antonia Lopez-Girona,
- Weili Miao,
- Sandy W. Wong,
- Jeffrey L. Wolf,
- Thomas G. Martin,
- Nina Shah,
- Scott Vandenberg,
- Sonam Prakash,
- Lenka Besse,
- Christoph Driessen,
- Avery D. Posey,
- R. Dyche Mullins,
- Justin Eyquem,
- James A. Wells,
- Arun P. Wiita
Affiliations
- Ian D. Ferguson
- Department of Laboratory Medicine, University of California
- Bonell Patiño-Escobar
- Department of Laboratory Medicine, University of California
- Sami T. Tuomivaara
- Department of Laboratory Medicine, University of California
- Yu-Hsiu T. Lin
- Department of Laboratory Medicine, University of California
- Matthew A. Nix
- Department of Laboratory Medicine, University of California
- Kevin K. Leung
- Department of Pharmaceutical Chemistry, University of California
- Corynn Kasap
- Department of Medicine, Division of Hematology/Oncology, University of California
- Emilio Ramos
- Department of Laboratory Medicine, University of California
- Wilson Nieves Vasquez
- Department of Cellular and Molecular Pharmacology, University of California
- Alexis Talbot
- Department of Medicine, Division of Hematology/Oncology, University of California
- Martina Hale
- Department of Laboratory Medicine, University of California
- Akul Naik
- Department of Laboratory Medicine, University of California
- Audrey Kishishita
- Department of Laboratory Medicine, University of California
- Priya Choudhry
- Department of Laboratory Medicine, University of California
- Antonia Lopez-Girona
- Bristol Myers Squibb/Celgene
- Weili Miao
- Program in Epithelial Biology, Stanford University School of Medicine
- Sandy W. Wong
- Department of Pharmaceutical Chemistry, University of California
- Jeffrey L. Wolf
- Department of Pharmaceutical Chemistry, University of California
- Thomas G. Martin
- Department of Pharmaceutical Chemistry, University of California
- Nina Shah
- Department of Pharmaceutical Chemistry, University of California
- Scott Vandenberg
- Department of Pathology, University of California
- Sonam Prakash
- Department of Laboratory Medicine, University of California
- Lenka Besse
- Department of Medical Oncology and Hematology, Kantonsspital St. Gallen
- Christoph Driessen
- Department of Medical Oncology and Hematology, Kantonsspital St. Gallen
- Avery D. Posey
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine
- R. Dyche Mullins
- Department of Medicine, Division of Hematology/Oncology, University of California
- Justin Eyquem
- Department of Pharmaceutical Chemistry, University of California
- James A. Wells
- Department of Pharmaceutical Chemistry, University of California
- Arun P. Wiita
- Department of Laboratory Medicine, University of California
- DOI
- https://doi.org/10.1038/s41467-022-31810-6
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
The myeloma cell surface proteome regulates plasma cell biology and delineates therapy targets. Here, the authors profile the myeloma surfaceome at baseline and in drug resistance, finding the potential target CCR10, and include a streamlined approach to primary sample analysis.
